Skip to content

Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial

Mortality Benefit of Ultrasound for Incidental Thyroid Nodules Identified With PET Imaging: A Non-Inferiority Emulated Target Trial

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07255482
Enrollment
874
Registered
2025-12-01
Start date
2025-10-15
Completion date
2026-08-04
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer, Thyroid Nodule (Benign), Thyroid Nodule (Diagnosis)

Brief summary

The investigators hypothesize that all-cause mortality in patients with an incidental thyroid nodule on PET-CT who did not have thyroid ultrasound (the exposure) within 3 months of the PET-CT is non-inferior within a 5% margin to those who have thyroid ultrasound at 7-years. That is, among patients with an incidental thyroid nodule on PET-CT, mortality is no more than 5% larger (in absolute difference) for those who do not have thyroid ultrasound compared to those who do. The investigators will also report mortality differences at landmark timeframes of 1-year, 3-years, 5-years, and 10-years. To estimate group differences in mortality, the investigators will conduct a non-inferiority emulated target trial utilizing clone-censor weighting to address potential immortal time bias introduced by the 3-month grace period. The investigators will adjust for demographic, potential confounder, and mortality risk adjustor factors. The investigators will stratify analyses based on baseline disease severity (estimated 5-year relative survival risk) and disease status (progression, lymph node involvement, other sites of metastases). All subjects will be accrued from the Mass General Brigham healthcare system, which includes two academic medical centers, a specialty head and neck hospital, and multiple community hospitals and numerous community clinics.

Detailed description

Study Hypothesis: The investigators hypothesize that all-cause mortality in patients with an incidental thyroid nodule on PET-CT who did not have thyroid ultrasound within 3 months is no worse than 5% lower than those who did have ultrasound. Outcome Measures: Primary Outcome: All-cause mortality. Secondary Outcomes: Numbers of thyroid cancer diagnoses, thyroid ultrasounds, thyroid biopsies, and thyroid surgeries Exploratory Outcomes: Types of thyroid cancer diagnoses Study Population: All patients age 18-years and older with incidental thyroid nodule on PET-CT performed between 1/1/2015 and 12/31/2021. Sites/Facilities: Mass General Brigham healthcare system including Massachusetts General Hospital, Brigham and Women's Hospital, Mass Eye and Ear, and associated community sites. Exposure: Thyroid ultrasound evaluation within 3-months of PET-CT.

Interventions

DIAGNOSTIC_TESTThyroid Ultrasound

Thyroid ultrasound performed within 3 months of PET to characterize a thyroid nodule identified on the PET

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER
Harvard School of Public Health (HSPH)
CollaboratorOTHER
Agency for Healthcare Research and Quality (AHRQ)
CollaboratorFED

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \>=18 2. Thyroid nodule on PET-CT performed 1/1/2015 to 12/31/2021 3. At least one clinical note in the EHR from the 36-month window prior to the PET

Exclusion criteria

1. Thyroid ultrasound listed in the medical record in the prior 3 years 2. Documented history of prior thyroid cancer diagnosis

Design outcomes

Primary

MeasureTime frame
All-Cause Mortality7 Years

Secondary

MeasureTime frame
Number of Thyroid Cancer Diagnoses7 Years
Number of Thyroid Ultrasound Examinations7 Years
Number of Thyroid Biopsies7 Years
Number of Thyroid Surgeries7 Years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026